JP2021527077A5 - - Google Patents

Info

Publication number
JP2021527077A5
JP2021527077A5 JP2020568685A JP2020568685A JP2021527077A5 JP 2021527077 A5 JP2021527077 A5 JP 2021527077A5 JP 2020568685 A JP2020568685 A JP 2020568685A JP 2020568685 A JP2020568685 A JP 2020568685A JP 2021527077 A5 JP2021527077 A5 JP 2021527077A5
Authority
JP
Japan
Prior art keywords
vaccine composition
composition according
subunit
seq
nanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020568685A
Other languages
English (en)
Japanese (ja)
Other versions
JP7555826B2 (ja
JP2021527077A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/036917 external-priority patent/WO2019241483A1/en
Publication of JP2021527077A publication Critical patent/JP2021527077A/ja
Publication of JP2021527077A5 publication Critical patent/JP2021527077A5/ja
Application granted granted Critical
Publication of JP7555826B2 publication Critical patent/JP7555826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020568685A 2018-06-13 2019-06-13 新規構造成分を含有するナノ粒子ワクチン Active JP7555826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684229P 2018-06-13 2018-06-13
US62/684,229 2018-06-13
PCT/US2019/036917 WO2019241483A1 (en) 2018-06-13 2019-06-13 Nanoparticle vaccines with novel structural components

Publications (3)

Publication Number Publication Date
JP2021527077A JP2021527077A (ja) 2021-10-11
JP2021527077A5 true JP2021527077A5 (enExample) 2022-06-20
JP7555826B2 JP7555826B2 (ja) 2024-09-25

Family

ID=68843607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020568685A Active JP7555826B2 (ja) 2018-06-13 2019-06-13 新規構造成分を含有するナノ粒子ワクチン

Country Status (12)

Country Link
US (2) US11097002B2 (enExample)
EP (1) EP3807210A4 (enExample)
JP (1) JP7555826B2 (enExample)
KR (1) KR20210021530A (enExample)
CN (1) CN112469661B (enExample)
AU (1) AU2019285048B2 (enExample)
CA (1) CA3103460A1 (enExample)
EA (1) EA202092808A1 (enExample)
IL (1) IL279351B2 (enExample)
SG (1) SG11202012313PA (enExample)
WO (1) WO2019241483A1 (enExample)
ZA (1) ZA202100032B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018358238B2 (en) * 2017-11-01 2022-08-18 The Scripps Research Institute Novel scaffolded HIV-1 vaccine immunogens
US11008368B2 (en) * 2019-07-26 2021-05-18 The Scripps Research Institute Engineered HCV E2 immunogens and related vaccine compositions
WO2021163365A1 (en) * 2020-02-11 2021-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 vaccine
PE20230486A1 (es) * 2020-02-14 2023-03-21 Univ Washington Polipeptidos y sus usos
CN113121704B (zh) * 2020-03-25 2023-04-07 昆山新蕴达生物科技有限公司 基于纳米颗粒的冠状病毒疫苗
US11278617B2 (en) 2020-03-31 2022-03-22 Engimata, Inc Immunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
CN112023035A (zh) * 2020-04-07 2020-12-04 中国医学科学院医学生物学研究所 一种以SARS-CoV-2病毒S蛋白RBD区为抗原的纳米疫苗及其制备
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20205382A1 (en) * 2020-04-09 2021-05-07 Niemelae Erik Method for preventing the spreading and lowering the infection rate of pathogens
JP2023521418A (ja) 2020-04-10 2023-05-24 インビビド, インコーポレイテッド コロナウイルスsタンパク質に特異的な化合物及びその使用
WO2021207730A1 (en) * 2020-04-11 2021-10-14 The Wistar Institute Of Anatomy & Biology Vaccines for coronavirus and methods of using the same
WO2021210984A1 (en) * 2020-04-17 2021-10-21 Erasmus University Medical Center Rotterdam Coronavirus vaccine
KR20220153767A (ko) * 2021-05-12 2022-11-21 (주)인테라 엔캡슐린 기반 뎅기 바이러스 또는 코로나 바이러스 백신 생산을 위한 재조합 발현 벡터 및 이의 제조방법
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2021262625A1 (en) * 2020-06-24 2021-12-30 Avalon GloboCare Corp. S-layer vaccine fusion proteins and methods of use
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
WO2022035739A2 (en) * 2020-08-10 2022-02-17 The Scripps Research Institute Compositions and methods related to ebola virusvaccines
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
KR20230116810A (ko) * 2020-11-03 2023-08-04 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 Dna 암호화 나노입자 및 코로나바이러스 질환 2019(covid-19) 백신으로서의 그것의 사용 방법
CN114349868B (zh) * 2020-12-01 2023-12-08 中国医学科学院基础医学研究所 一种含寡聚化结构域的新型冠状病毒s蛋白受体结合域融合蛋白及其用途
WO2022133255A2 (en) * 2020-12-18 2022-06-23 The Scripps Research Institute Immunogenic compositions
EP4262864A4 (en) * 2020-12-18 2025-06-04 The Scripps Research Institute IMMUNOGENIC COMPOSITIONS
US20240252617A1 (en) * 2021-02-10 2024-08-01 Duke University Coronavirus spike protein designs, compositions and methods for their use
CN112979826B (zh) * 2021-03-03 2022-04-08 华中农业大学 一种乙型脑炎病毒纳米颗粒疫苗及其制备方法和应用
US20230181717A1 (en) * 2021-12-14 2023-06-15 The Scripps Research Institute Methods and compositions related to hiv-1 nanoparticle vaccines with improved properties
WO2024006532A2 (en) * 2022-06-30 2024-01-04 La Jolla Institute For Immunology Kari nanoparticle
WO2024050452A2 (en) * 2022-08-30 2024-03-07 Administrators Of The Tulane Educational Fund Compositions and methods for raising immune responses to gram-negative bacteria
CN115894716B (zh) * 2022-11-23 2024-02-09 华中农业大学 一种重组融合蛋白纳米颗粒及其制备方法
WO2024123558A2 (en) * 2022-12-05 2024-06-13 The Scripps Research Institute Engineered lassa viral immunogens and vaccine compositions
AU2024280139A1 (en) 2023-05-30 2026-01-22 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine composition, method therefor and use thereof
CN121464149A (zh) 2023-06-07 2026-02-03 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途
CN121758569A (zh) * 2023-11-03 2026-03-31 广东蓝玉生物科技有限公司 非洲猪瘟病毒p15蛋白的免疫原性组合物及其应用
CN121758570A (zh) * 2023-11-03 2026-03-31 广东蓝玉生物科技有限公司 非洲猪瘟病毒CD2v蛋白的免疫原性组合物及其应用
CN120923628A (zh) * 2024-05-09 2025-11-11 菲鹏生物股份有限公司 融合抗原及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
AU2006232310B9 (en) 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US7939083B2 (en) 2006-10-23 2011-05-10 Progenics Pharmaceuticals Inc. Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
CA2713879C (en) 2008-02-01 2020-01-07 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
EP2391635B1 (en) * 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA2772572A1 (en) 2009-08-31 2011-03-03 Ibc Pharmaceuticals, Inc. Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
CA2851917A1 (en) * 2011-10-12 2013-04-18 Alpha-O Peptides Ag Self-assembling peptide nanoparticles as vaccines against infection with norovirus
EP2765138B1 (en) 2012-11-05 2018-01-10 International Aids Vaccine Initiative HIV-1 envelope glycoprotein
SG10201705880QA (en) 2013-01-07 2017-08-30 Beth Israel Deaconess Medical Ct Inc Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
WO2014140882A2 (en) * 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
JP6652500B2 (ja) 2014-01-09 2020-02-26 アルファ−オ ペプティデス アクツィエンゲゼルシャフト ワクチンプラットフォームとしてのフラジェリン含有タンパク質ナノ粒子
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
WO2016138525A1 (en) 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
IL299962A (en) * 2016-05-02 2023-03-01 Scripps Research Inst Compositions and methods related to HIV-1 immunogens
PT3512543T (pt) 2016-09-15 2020-10-13 Janssen Vaccines & Prevention Bv Trímero que estabiliza mutações das proteínas do envelope do hiv
EP3600402A1 (en) * 2017-03-23 2020-02-05 Alpha-O Peptides AG Self-assembling protein nanoparticles with built-in six-helix bundle proteins
WO2018187515A1 (en) * 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
AU2018358238B2 (en) 2017-11-01 2022-08-18 The Scripps Research Institute Novel scaffolded HIV-1 vaccine immunogens
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Similar Documents

Publication Publication Date Title
JP2021527077A5 (enExample)
JP7555826B2 (ja) 新規構造成分を含有するナノ粒子ワクチン
AU2007239354B2 (en) N protein fusion proteins of a virus in the Paramyxoviridae-protein of interest family
AU2014230822B2 (en) Heat-stable Respiratory Syncytial Virus prefusion F protein oligomers and their use in immunological compositions
JP5751741B2 (ja) 免疫原性組成物および使用法
US9801927B2 (en) Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof
JP2008529558A5 (enExample)
JP2021502807A5 (enExample)
CA2925201A1 (en) Self-assembled nanoparticle vaccines
JP2008530245A5 (enExample)
AU2016289492A1 (en) Vaccine against RSV
JP2019522626A5 (enExample)
JP2010500399A5 (enExample)
JP2009544614A5 (enExample)
IL274130B2 (en) Novel scaffolded hiv-1 vaccine immunogens
CN107849558A (zh) 2型人副流感病毒载体和疫苗
US20210309973A1 (en) Bacteriophage-Based Antibodies and Binders
US20210401969A1 (en) Rsv virus-like particles and methods of use thereof
CN107344969B (zh) 一种纳米流感疫苗及构建方法和应用
CA2450548C (en) Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments
CN110234347A (zh) 使用了非感染性副粘病毒粒子的传染病疫苗
US20230355737A1 (en) Particle comprising an rsv-f protein for use in rsv vaccination
JP2024545833A (ja) コロナウイルス科ウイルスによる感染症の処置または予防のためのウイルス様粒子
CN117177766A (zh) 疫苗平台
JP2025509352A5 (enExample)